The Cambridge-based vaccine developer said a study done by an independent board found that the potential vaccine “did not meet the statistical threshold necessary to declare early success.'
Moderna shares slipped Tuesday morning after the COVID-19 vaccine developer said its potential flu vaccine needs more study in a late-stage clinical trial.
The company said an independent data and safety monitory board found that the potential vaccine “did not meet the statistical threshold necessary to declare early success” in the study.Moderna is developing the vaccine, labeled mRNA-1010, to guard against seasonal flu. It is testing the vaccine in two, late-stage studies in the Southern and Northern hemispheres.The company’s COVID-19 vaccine, Spikevax, has been its main revenue generator so far.
Moderna also is developing potential vaccines for respiratory syncytial virus, or RSV, and the human immunodeficiency virus that causes AIDS.The stock had already slipped about 11% so far this year. The Dow Jones Industrial Average has climbed slightly.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Fire damages Cambridge church after Easter servicesOver a hundred firefighters fought to save the 114-year-old Faith Lutheran Church in Cambridge shortly after Easter services yesterday. No injuries were reported.
Les mer »
Faith Lutheran Church in Cambridge, MA engulfed in flames in large fire after Easter MassA 6-alarm fire that engulfed a Massachusetts church just hours after Easter Sunday service was under investigation, fire officials said.
Les mer »
Faith Lutheran Church in Cambridge, MA engulfed in flames in large fire after Easter MassFaith Lutheran Church in Cambridge was empty when the fire started and no one was injured, fire officials reported.
Les mer »
Moderna says potential flu vaccine needs more studyModerna shares slipped Tuesday morning after the COVID-19 vaccine developer said its potential flu vaccine needs more study in a late-stage clinical trial.
Les mer »
Moderna is developing a vaccine candidate against Lyme disease that would be its first bacterial vaccineModerna Inc. outlined its clinical goals for its mRNA platform on Tuesday to mark its 4th Vaccine Day, including a new development candidate against Lyme...
Les mer »
Moderna to keep testing flu shot as it fails to meet 'early success' criteriaModerna said on Tuesday it had not enrolled enough cases in a late-stage trial of its experimental flu vaccine to determine if the shot was successful or not.
Les mer »